Company Overview
About Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Business Model & Competitive Advantage
In January 2025, Saluda received US FDA approval for EVA, its biomarker-based automated patient programming platform for SCS, which autonomously scans and analyzes a patient''s neural responses to optimize therapy settings — reducing the burden on both clinicians and patients during programming. Simultaneously, the company closed $100 million in new financing to accelerate commercialization of the Evoke system in the US. At the 2025 North American Neuromodulation Society (NANS) Annual Meeting, Saluda presented 11 abstracts and four oral presentations, two of which received Top Oral Abstract awards, including new 36-month efficacy data for the Evoke system.
Competitive Landscape 2025–2026
Saluda competes in the SCS market against Medtronic, Boston Scientific, Abbott, and Nevro. Its differentiation lies in the ECAP-based closed-loop control system, which is protected by an extensive patent portfolio. The company targets the estimated 1.5 million patients with chronic intractable back and leg pain who are candidates for SCS therapy in the US alone.
Key Differentiators
Market Leader
Saluda Medical is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare Saluda Medical with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Saluda Medical? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Saluda Medical Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Saluda Medical vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →